Solid Biosciences Inc(SLDB) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.91 | Insider Own | 18.41% | Shs Outstand | 105.1M | Perf Week | -3.28% |
| Market Cap | 0.66B | Forward P/E | - | EPS next Y | 2.65% | Insider Trans | -0.02% | Shs Float | 87.5M | Perf Month | -14.97% |
| Enterprise Value | 0.31B | PEG | - | EPS next Q | -0.41 | Inst Own | 90.54% | Short Float | 14.06% | Perf Quarter | -23.01% |
| Income | -0.21B | P/S | - | EPS this Y | 12.61% | Inst Trans | 13.04% | Short Ratio | 10.58 | Perf Half Y | -16.91% |
| Sales | 0.00B | P/B | 1.74 | EPS next 5Y | 17.4% | ROA | -56.83% | Short Interest | 12.30M | Perf YTD | 9.75% |
| Book/sh | 3.56 | P/C | 1.75 | EPS past 3/5Y | 41.79% 39.94% | ROE | -65.5% | 52W High | -45.94% ($11.45) | Perf Year | 4.92% |
| Cash/sh | 3.53 | P/FCF | - | Sales past 3/5Y | - | ROIC | -52.83% | 52W Low | 63.32% ($3.79) | Perf 3Y | 227.51% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 31.81% | Gross Margin | - | Volatility(W/M) | 6.61% 6.79% | Perf 5Y | -78.73% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.45 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 13.82 | EPS Q/Q | 9.06% | Profit Margin | - | RSI (14) | 41.41 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 13.82 | Sales Q/Q | - | SMA20 | -3.04% ($6.38) | Beta | 2.64 | Target Price | $18.71 |
| Payout | - | Debt/Eq | 0.05 | Earnings | 2026/8/6 | SMA50 | -22.53% ($7.99) | Rel Volume | 1.33 | Prev Close | $5.81 |
| Employees | 121 | LT Debt/Eq | 0.05 | EPS/Sales Surpr. | 17.82% - | SMA200 | -19.04% ($7.65) | Avg Volume(3M) | 1.16M | Price | $6.19 |
| IPO | 2018/1/26 | Option/Short | Yes/Yes | Trades | 6184 | Volume | 1,550,982 | Change | 6.54% |
🧬 Solid Biosciences (SLDB) is a US clinical-stage biotech developing precision gene therapies targeting neuromuscular and cardiac diseases. With its lead candidate SGT-003 for Duchenne muscular dystrophy, the company is advancing both pipeline expansion and licensing strategies based on its proprietary adeno-associated virus capsid technology.
Over the past 1 year, roughly in the middle
46% below its 1-year high.
Traded more than usual. That is 133% of its average volume.
SLDB has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +12.6% this year.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -78.7%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 90.5%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #193 of 594 in the industry
Based on market cap of $664M.
IMMX#191 Immix Biopharma Inc $667M PER - 
DSGN#192 Design Therapeutics Inc $665M PER - SLDB#193 Solid Biosciences Inc $664M PER - 
IAM#194 Iambic Therapeutics Inc $664M PER - 
FDMT#195 4D Molecular Therapeutics Inc $661M PER - 
FAQ
What kind of company is SLDB?
SLDB belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of SLDB?
The market cap of SLDB is approximately $664M, ranking 2,927 within its sector.
What is the 52-week high and low for SLDB?
SLDB has recorded a 52-week high of $11.45 and a low of $3.79.
